No actionable trading signal. This is a standard post-annual meeting filing with routine director elections and equity plan amendments. Monitor for operational or pipeline updates from upcoming earnings or press releases.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 11 $6.31entry
- T+1 · 5mo ago +2.38%α +1.84% · $6.46
- T+5 · 5mo ago +7.92%α +7.49% · $6.81
- T+20 · 4mo ago +17.27%α +15.38% · $7.40
- T+60 · 2mo ago +13.00%α +8.60% · $7.13
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Entrada Therapeutics filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders. Stockholders approved amendments to the company's 2021 Stock Option and Incentive Plan and 2021 Employee Stock Purchase Plan to include pre-funded warrants in the evergreen share calculation. Two Class II directors were elected and Ernst & Young was ratified as auditor. This is a routine governance filing with no material financial impact.
Key Facts
- Stockholders approved Amendment No. 1 to the 2021 Stock Option and Incentive Plan and the 2021 Employee Stock Purchase Plan, adding pre-funded warrants to the evergreen formula's outstanding share count.
- Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D. were elected as Class II directors.
- Ernst & Young LLP was ratified as independent auditor for fiscal year 2026.
- 38,820,616 shares outstanding as of record date April 13, 2026; 33,190,234 shares present at meeting.
- The 2021 Plan Amendment passed with 14,686,713 for, 9,566,186 against; the ESPP Amendment passed with 16,780,217 for, 7,475,514 against.
Financial Impact
No financial impact. The equity plan amendments are administrative and do not change share reserve amounts or dilutive limits directly.
Risk Factors
- No material risks identified in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-072326 |
| Document: tm2617532d1_ex10-1.htm | 0001104659-26-072326 |
| Document: tm2617532d1_ex10-2.htm | 0001104659-26-072326 |
| Document: 0001104659-26-072326-index-headers.html | 0001104659-26-072326 |
| Document: 0001104659-26-072326-index.html | 0001104659-26-072326 |
| Document: 0001104659-26-072326.txt | 0001104659-26-072326 |
Track record
21 reports on TRDA
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +58.22% at T+20 after the May 4, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $4.55 Now $5.00 +9.89% settles Feb 3
- Oct 14, 20264w ago 8-K Bullish 6/10 Entry $4.55 Now $5.00 +9.89% settles Jan 11
- Sep 9, 20269w ago Insider Cluster Bearish 6/10 Entry $6.42 Now $5.00 +22.12% settles Dec 4
- Sep 3, 202610w ago Insider Cluster Neutral 3/10 Entry $7.13 Now $5.00 −29.87% settles Dec 1
- Aug 31, 202611w ago Insider Cluster Neutral 4/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 31, 202611w ago Insider Cluster Neutral 4/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 31, 202611w ago Insider Cluster Neutral 3/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $7.27 Now $5.00 −31.22% settles Nov 20
- Aug 10, 202614w ago Insider Cluster Neutral 2/10 Entry $7.04 to $5.06 Now $5.00 −28.98% ▼ −28.13% −27.64% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers